Mañana, JUEVES, 24 DE ABRIL, el sistema se apagará debido a tareas habituales de mantenimiento a partir de las 9 de la mañana. Lamentamos las molestias.
Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment
dc.contributor.author | Provencio Pulla, Mariano | |
dc.contributor.author | Torrente, María | |
dc.contributor.author | Calvo de Juan, Virginia | |
dc.contributor.author | Gutiérrez, Lourdes | |
dc.contributor.author | Pérez-Callejo, David | |
dc.contributor.author | Pérez-Barrios, Clara | |
dc.contributor.author | Barquín, Miguel | |
dc.contributor.author | Royuela Vicente, Ana | |
dc.contributor.author | Rodríguez-Alfonso, Begoña | |
dc.contributor.author | Sotelo, Miguel | |
dc.contributor.author | Cruz-Bermúdez, Juan Luis | |
dc.contributor.author | Mendez, Miriam | |
dc.contributor.author | Cruz-Bermúdez, Alberto | |
dc.contributor.author | Romero, Atocha | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.date.accessioned | 2018-02-09T18:45:00Z | |
dc.date.available | 2018-02-09T18:45:00Z | |
dc.date.issued | 2017-08-07 | |
dc.identifier.citation | Oncotarget 8.36 (2017): 60291-60298 | es_ES |
dc.identifier.issn | 1949-2553 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/681155 | |
dc.description.abstract | Background: Liquid biopsy has evolved from being a promising line to becoming a validated approach for biomarker testing. However, its utility for individualization of therapy has been scarcely reported. In this study, we show how monitoring levels of EGFR mutation in plasma can be useful for the individualization of treatment. Results: Longitudinal EGFR mutation levels in plasma always correlated with tumor response ascertained by RECIST criteria. Moreover, decreasing EGFR mutation levels were detected in all patients benefiting from locoregional radiotherapy, whereas the opposite occurred when a patient progressed soon after radiotherapy treatment. Similarly, increasing EGFR mutation levels anticipated disease progression after TKI dose reduction, discontinuation of treatment, or reduced bioavailability due to drug interactions. In addition, EGFR mutation levels were useful to monitor treatment outcome of new therapies and constituted a decisive factor when the clinical situation of the patient did not correlate with responses ascertained by radiologist. Finally, our results indicate that cancer associated body fluids (pleural, pericardial or cerebrospinal fluid) are certainly a suitable source for biomarker testing that can extend EGFR mutation detection to biofluids other than blood. Materials and Methods: A total of 180 serial plasma samples from 18 non-smallcell lung cancer patients who carried an activating EGFR mutation were investigated by digital PCR. Conclusions: Monitoring levels of EGFR mutation in plasma allows resolving doubts that frequently arise in daily clinical practice and constitutes a major step towards achieving personalized medicine | es_ES |
dc.description.sponsorship | This study was supported by Carlos III Institute of Health, Spanish Ministry of Science and Innovation, and European Regional Development Fund (grant number: PI16/01818 and PIE14/00064), A Romero is supported by Joan Rodés fellowship (grant number: JR14/00017) and CP pre-doctoral studies are supported by Jose Luís Castaño Foundation | es_ES |
dc.format.extent | 8 pag. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Impact Journals | es_ES |
dc.relation.ispartof | Oncotarget | es_ES |
dc.rights | © 2017 Provencio et al. | es_ES |
dc.subject.other | cfDNA | es_ES |
dc.subject.other | TKI | es_ES |
dc.subject.other | Personalized medicine | es_ES |
dc.subject.other | Lung cancer | es_ES |
dc.subject.other | Liquid biopsy | es_ES |
dc.title | Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment | es_ES |
dc.type | article | es_ES |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | http://doi.org/10.18632/oncotarget.20016 | es_ES |
dc.identifier.doi | 10.18632/oncotarget.20016 | es_ES |
dc.identifier.publicationfirstpage | 60291 | es_ES |
dc.identifier.publicationissue | 36 | es_ES |
dc.identifier.publicationlastpage | 60298 | es_ES |
dc.identifier.publicationvolume | 8 | es_ES |
dc.relation.projectID | Gobierno de España. PI16/01818 | es_ES |
dc.relation.projectID | Gobierno de España. PIE14/00064 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.authorUAM | Provencio Pulla, Mariano (262376) | |
dc.facultadUAM | Facultad de Medicina |